Rudy Li
Stock Analyst at Wolfe Research
(4.91)
# 230
Out of 4,592 analysts
78
Total ratings
57.4%
Success rate
75.7%
Average return
Main Sectors:
Stocks Rated by Rudy Li
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Upgraded: Buy | $65 | $43.63 | +48.98% | 2 | Jul 29, 2026 | |
| CMPS COMPASS Pathways | Maintained: Buy | $18 | $11.35 | +58.59% | 1 | Jul 7, 2026 | |
| LBRX LB Pharmaceuticals | Initiated Coverage: Buy | $45 | $40.08 | +12.28% | 1 | Jul 7, 2026 | |
| SPTX Seaport Therapeutics | Initiated Coverage: Hold | n/a | $20.46 | - | 1 | Jul 7, 2026 | |
| ACAD ACADIA Pharmaceuticals | Reiterated: Buy | $33 | $25.87 | +27.56% | 2 | May 6, 2026 | |
| NBIX Neurocrine Biosciences | Reiterated: Buy | $160 | $166.80 | -4.08% | 2 | Apr 6, 2026 | |
| PRAX Praxis Precision Medicines | Maintained: Buy | $500 | $307.83 | +62.43% | 7 | Apr 6, 2026 | |
| ALKS Alkermes | Initiated Coverage: Buy | $45 | $48.99 | -8.14% | 2 | Feb 23, 2026 | |
| XENE Xenon Pharmaceuticals | Initiated Coverage: Buy | $55 → $60 | $62.67 | -4.26% | 5 | Feb 23, 2026 | |
| AXSM Axsome Therapeutics | Initiated Coverage: Buy | $230 | $217.99 | +5.51% | 1 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 → $25 | $43.52 | -42.56% | 11 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | €340.00 | €217.88 | +56.05% | 1 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $23.02 | - | 1 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $24 → $40 | $28.86 | +38.60% | 19 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $8.12 | +121.67% | 15 | Dec 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $13.97 | +114.75% | 2 | Dec 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $27.07 | -44.59% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $40 | $0.43785 | +9,035.55% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $80 | $73.26 | n/a | 2 | May 21, 2025 |
uniQure
Jul 29, 2026
Upgraded: Buy
Price Target: $65
Current: $43.63
Upside: +48.98%
COMPASS Pathways
Jul 7, 2026
Maintained: Buy
Price Target: $18
Current: $11.35
Upside: +58.59%
LB Pharmaceuticals
Jul 7, 2026
Initiated Coverage: Buy
Price Target: $45
Current: $40.08
Upside: +12.28%
Seaport Therapeutics
Jul 7, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $20.46
Upside: -
ACADIA Pharmaceuticals
May 6, 2026
Reiterated: Buy
Price Target: $33
Current: $25.87
Upside: +27.56%
Neurocrine Biosciences
Apr 6, 2026
Reiterated: Buy
Price Target: $160
Current: $166.80
Upside: -4.08%
Praxis Precision Medicines
Apr 6, 2026
Maintained: Buy
Price Target: $500
Current: $307.83
Upside: +62.43%
Alkermes
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $45
Current: $48.99
Upside: -8.14%
Xenon Pharmaceuticals
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $55 → $60
Current: $62.67
Upside: -4.26%
Axsome Therapeutics
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $230
Current: $217.99
Upside: +5.51%
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $20 → $25
Current: $43.52
Upside: -42.56%
Feb 23, 2026
Initiated Coverage: Buy
Price Target: €340.00
Current: €217.88
Upside: +56.05%
Feb 23, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $23.02
Upside: -
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $24 → $40
Current: $28.86
Upside: +38.60%
Dec 31, 2025
Initiated Coverage: Buy
Price Target: $18
Current: $8.12
Upside: +121.67%
Dec 31, 2025
Initiated Coverage: Buy
Price Target: $30
Current: $13.97
Upside: +114.75%
Oct 20, 2025
Maintained: Buy
Price Target: $15
Current: $27.07
Upside: -44.59%
Sep 29, 2025
Initiated Coverage: Buy
Price Target: $40
Current: $0.43785
Upside: +9,035.55%
May 21, 2025
Reiterated: Buy
Price Target: $80
Current: $73.26
Upside: n/a